Skip to main content
logo
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
21.71
-0.50 (-2.25%)
At close: Mar 12, 2026, 4:00 PM EDT
21.51
-0.20 (-0.92%)
Pre-market: Mar 13, 2026, 6:00 AM EDT

Ultragenyx Pharmaceutical Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Cap
2,0932,2223,8913,9363,2525,831
Market Cap Growth
-44.53%-42.91%-1.14%21.03%-44.23%-36.96%
Enterprise Value
2,6081,5733,3183,3902,5245,122
Last Close Price
21.7123.0042.0747.8246.3384.09
PE Ratio
--3.95-6.69-5.80-4.58-12.55
PS Ratio
3.113.306.959.078.9516.59
PB Ratio
--27.7715.2614.299.236.32
P/TBV Ratio
-26.76-28.3514.9312.769.196.18
P/FCF Ratio
--4.71-9.24-7.58-6.55-14.16
P/OCF Ratio
--4.77-9.40-8.29-8.55-17.22
EV/Sales Ratio
3.882.345.937.816.9514.58
EV/EBITDA Ratio
--3.15-6.64-6.24-4.00-13.90
EV/EBIT Ratio
--2.94-6.19-5.96-3.89-13.42
EV/FCF Ratio
--3.33-7.88-6.53-5.08-12.44
Debt / Equity Ratio
-0.33-0.330.110.110.060.03
Debt / EBITDA Ratio
-0.07-0.07-0.08-0.08-0.05-0.11
Debt / FCF Ratio
-0.08-0.08-0.09-0.08-0.06-0.10
Net Debt / Equity Ratio
8.058.05-2.23-1.94-2.03-0.76
Net Debt / EBITDA Ratio
1.291.291.140.981.141.90
Net Debt / FCF Ratio
1.361.361.351.031.441.70
Asset Turnover
0.440.440.370.290.240.21
Inventory Turnover
2.252.251.951.481.321.09
Quick Ratio
2.182.182.132.323.024.24
Current Ratio
2.482.482.382.613.384.72
Return on Equity (ROE)
-608.47%-608.47%-211.75%-193.34%-110.96%-43.72%
Return on Assets (ROA)
-35.50%-35.50%-35.93%-37.35%-42.65%-23.32%
Return on Invested Capital (ROIC)
-92.17%-92.17%-83.51%-92.60%-111.90%-72.46%
Return on Capital Employed (ROCE)
-46.38%-46.38%-45.24%-45.61%-49.44%-26.23%
Earnings Yield
-27.47%-25.35%-14.95%-17.25%-21.84%-7.97%
FCF Yield
-22.55%-21.24%-10.82%-13.18%-15.27%-7.06%
Buyback Yield / Dilution
-3.87%-3.87%-10.07%-9.83%-0.33%-2.04%
Updated Feb 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q